We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | 장 마감 후 (AMC) | $-0.63 | — | — | $0 | — | 예정 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-22.63 | — | — | $249K | 보고됨 |
| FY2024 Q3 | 2023. 09. 30. | 시각 미정 | — | $-231.05 | — | — | $1.35M |
Consensus PT $46.18 · 11 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Citizens | — | 의견 유지 | Market Outperform → Market Outperform | — | Citizens: Market Outperform |
| 2026. 05. 14. | Wedbush | — | 의견 유지 | Outperform → Outperform | — | Wedbush: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2024 Q2 | 2023. 06. 30. | 시각 미정 | — | $-338.85 | — | — | $1.12M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 916,142 | $13.68B | 0.02% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 627,502 | $11.4B | 0.02% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Stored first · Google News · Yahoo Finance (English)
Avalo Therapeutics (AVTX) CMO sells shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics (AVTX) CMO sells shares under 10b5-1 plan Stock Titan
Deep Track holds 5.81% of Avalo Therapeutics (AVTX) in Schedule 13G filing - Stock Titan
Deep Track holds 5.81% of Avalo Therapeutics (AVTX) in Schedule 13G filing Stock Titan
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) - ChartMill
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) ChartMill
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58 - 富途牛牛
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58 富途牛牛
Point72 (AVTX) reports 2.71M-share, 5.2% position in Avalo Therapeutics - Stock Titan
Point72 (AVTX) reports 2.71M-share, 5.2% position in Avalo Therapeutics Stock Titan
Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028 - Stock Titan
Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028 Stock Titan